INMB INMUNE BIO INC US FDA Inspections 8-K Filing 2024 - FDA Clinical Hold Lifted INmune Bio Inc. announced that the FDA has lifted the clinical hold on its Alzheimer's disease clinical trial program, with patient enrollment expected to be complete in mid-2024 and top line data expected six months after the last patient is enrolled.Get access to all SEC 8-K filings of the INMUNE BIO INC